$NWBO
NORTHWEST BIOTHERAPEUTICS INC

2021 Q1 Form 10-Q Financial Statement

#000110465921068299 Filed on May 17, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $239.0K $570.0K
YoY Change -58.07% 68.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.89M $4.546M
YoY Change 183.46% -10.88%
% of Gross Profit
Research & Development $6.923M $3.857M
YoY Change 79.49% 28.4%
% of Gross Profit
Depreciation & Amortization $68.00K $14.00K
YoY Change 385.71% 600.0%
% of Gross Profit
Operating Expenses $6.923M $3.857M
YoY Change 79.49% 28.4%
Operating Profit -$19.57M -$7.833M
YoY Change 149.84% 0.86%
Interest Expense $1.447M $625.0K
YoY Change 131.52% -17.33%
% of Operating Profit
Other Income/Expense, Net $15.45M $10.46M
YoY Change 47.69% -179.36%
Pretax Income -$4.123M $2.726M
YoY Change -251.25% -113.01%
Income Tax
% Of Pretax Income
Net Earnings -$4.123M $2.626M
YoY Change -257.01% -112.54%
Net Earnings / Revenue -1725.1% 460.7%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 834.6K 640.4K
Diluted Shares Outstanding 834.6K 648.9K

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.468M $764.0K
YoY Change 877.49% -95.31%
Cash & Equivalents $7.468M $764.0K
Short-Term Investments
Other Short-Term Assets $5.749M $2.844M
YoY Change 102.14% 24.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.22M $3.608M
YoY Change 266.32% -80.58%
LONG-TERM ASSETS
Property, Plant & Equipment $1.234M $4.822M
YoY Change -74.41% 1640.79%
Goodwill $626.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.070M $753.0K
YoY Change 42.1% 0.67%
Total Long-Term Assets $19.24M $5.575M
YoY Change 245.17% -5.33%
TOTAL ASSETS
Total Short-Term Assets $13.22M $3.608M
Total Long-Term Assets $19.24M $5.575M
Total Assets $32.46M $9.183M
YoY Change 253.48% -62.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.44M $7.996M
YoY Change 30.62% -55.69%
Accrued Expenses $170.0K $384.0K
YoY Change -55.73% 42.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.374M $12.32M
YoY Change -80.72% -12.32%
Total Short-Term Liabilities $363.4M $39.66M
YoY Change 816.33% -46.56%
LONG-TERM LIABILITIES
Long-Term Debt $16.69M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $5.560M $4.516M
YoY Change 23.12% -4.91%
Total Long-Term Liabilities $22.25M $4.516M
YoY Change 392.71% -48.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $363.4M $39.66M
Total Long-Term Liabilities $22.25M $4.516M
Total Liabilities $385.7M $44.18M
YoY Change 773.03% -46.76%
SHAREHOLDERS EQUITY
Retained Earnings -$1.375B
YoY Change
Common Stock $1.023B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$353.2M -$36.58M
YoY Change
Total Liabilities & Shareholders Equity $32.46M $9.183M
YoY Change 253.48% -62.47%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$4.123M $2.626M
YoY Change -257.01% -112.54%
Depreciation, Depletion And Amortization $68.00K $14.00K
YoY Change 385.71% 600.0%
Cash From Operating Activities -$13.25M -$7.539M
YoY Change 75.73% -22.68%
INVESTING ACTIVITIES
Capital Expenditures -$264.0K -$62.00K
YoY Change 325.81% -62.2%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$264.0K -$62.00K
YoY Change 325.81% -62.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.76M 7.025M
YoY Change 53.18% 78.34%
NET CHANGE
Cash From Operating Activities -13.25M -7.539M
Cash From Investing Activities -264.0K -62.00K
Cash From Financing Activities 10.76M 7.025M
Net Change In Cash -2.515M 392.0K
YoY Change -741.58% -106.56%
FREE CASH FLOW
Cash From Operating Activities -$13.25M -$7.539M
Capital Expenditures -$264.0K -$62.00K
Free Cash Flow -$12.98M -$7.477M
YoY Change 73.65% -22.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 dei Entity Address Country
EntityAddressCountry
MD
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
NORTHWEST BIOTHERAPEUTICS INC
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001072379
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
842400000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
829600000
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-35737
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3306718
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4800 Montgomery Lane, Suite 800
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2021Q1 dei City Area Code
CityAreaCode
240
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
497-9024
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Security12g Title
Security12gTitle
Common Stock, par value $0.001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
NWBO
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
851564728
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7468000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9983000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5749000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5528000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
13217000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
15511000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1234000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1040000
CY2021Q1 nwbo Constructions In Progress Net
ConstructionsInProgressNet
9881000
CY2020Q4 nwbo Constructions In Progress Net
ConstructionsInProgressNet
9074000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5140000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4489000
CY2021Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2021Q1 us-gaap Goodwill
Goodwill
626000
CY2020Q4 us-gaap Goodwill
Goodwill
626000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1070000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
867000
CY2021Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
19243000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
17388000
CY2021Q1 us-gaap Assets
Assets
32460000
CY2020Q4 us-gaap Assets
Assets
32899000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7471000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7380000
CY2021Q1 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
2973000
CY2020Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
5363000
CY2021Q1 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
135000
CY2020Q4 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
3830000
CY2021Q1 us-gaap Notes Payable Current
NotesPayableCurrent
2239000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2437000
CY2021Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8554000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8275000
CY2021Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
341867000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
354972000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
170000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
167000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
363409000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
382424000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
842400000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
829600000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
842000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
830000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1021900000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1008665000
CY2021Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2020Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1375339000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1371216000
CY2021Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
16691000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8507000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5560000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4916000
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
22251000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13423000
CY2021Q1 us-gaap Liabilities
Liabilities
385660000
CY2020Q4 us-gaap Liabilities
Liabilities
395847000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-524000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1148000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-353200000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-362948000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32460000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32899000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
239000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
570000
CY2021Q1 us-gaap Revenues
Revenues
239000
CY2020Q1 us-gaap Revenues
Revenues
570000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6923000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3857000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12886000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4546000
CY2021Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
19809000
CY2020Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
8403000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19570000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7833000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17563000
CY2020Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
12927000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8000
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-715000
CY2021Q1 us-gaap Interest Expense
InterestExpense
1447000
CY2020Q1 us-gaap Interest Expense
InterestExpense
625000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-661000
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1128000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15447000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10459000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4123000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
2626000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-624000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-1041000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3499000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3667000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
834605
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
640390
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
834605
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
648858
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-362948000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16000
CY2021Q1 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
6619000
CY2021Q1 nwbo Value Of Warrants And Stock Options Exercised For Cash
ValueOfWarrantsAndStockOptionsExercisedForCash
745000
CY2021Q1 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
2935000
CY2021Q1 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
146000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9891000
CY2021Q1 nwbo Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise
-7105000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4123000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
624000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-353200000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-45055000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2020Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2045000
CY2020Q1 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
2399000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
364000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
2626000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1041000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-36580000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4123000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
2626000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
68000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14000
CY2021Q1 nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
1126000
CY2020Q1 nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
343000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17563000
CY2020Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
12927000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8000
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-715000
CY2021Q1 nwbo Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
93000
CY2020Q1 nwbo Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
80000
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
9818000
CY2020Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
364000
CY2021Q1 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-6450000
CY2020Q1 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-11411000
CY2021Q1 nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
286000
CY2020Q1 nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
78000
CY2021Q1 nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
198000
CY2021Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
876000
CY2020Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1208000
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-3128000
CY2020Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
81000
CY2021Q1 nwbo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
61000
CY2020Q1 nwbo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
35000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13248000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7539000
CY2021Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
264000
CY2020Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
62000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-264000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62000
CY2021Q1 nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
16000
CY2020Q1 nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
5671000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
745000
CY2021Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000
CY2020Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1000000
CY2020Q1 us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
240000
CY2020Q1 nwbo Proceeds From Advances To Investor
ProceedsFromAdvancesToInvestor
178000
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
64000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10761000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7025000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
236000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
968000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2515000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
392000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9983000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
372000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7468000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
764000
CY2021Q1 nwbo Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise
StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise
5000
CY2021Q1 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
2935000
CY2021Q1 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
146000
CY2021Q1 nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
6742000
CY2020Q1 nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
1789000
CY2020Q1 nwbo Offering Cost Related To Warrant Liability
OfferingCostRelatedToWarrantLiability
2606000
CY2021Q1 nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
753000
CY2020Q1 nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
405000
CY2020Q4 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8275000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
365754000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
365754000
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
131000
CY2021Q1 nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash
-4024000
CY2021Q1 nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Debt Conversion
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToDebtConversion
-1925000
CY2020Q1 nwbo Warrants Issued Associated With Convertible Notes Payable To Related Party
WarrantsIssuedAssociatedWithConvertibleNotesPayableToRelatedParty
79000
CY2020Q1 nwbo Warrant Modification In Connection With Debt Amendment
WarrantModificationInConnectionWithDebtAmendment
315000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include recoverability and useful lives (indefinite) of intangible asset, assessment of impairment of goodwill, valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply.</p>
CY2021Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
341867000
CY2021Q1 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8554000
CY2021Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
350421000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
354972000
CY2020Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2507000
CY2021Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-17563000
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
350421000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9818000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
364000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7400000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
308840
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
372219000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
183
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.25
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3695
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
304962
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
354723000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
254385
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.30
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
276262000
CY2021Q1 nwbo Share Based Compensation Arrangement By Share Based Payment Award Period Of Notice For Exercising Any Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfNoticeForExercisingAnyOption
P61D
CY2021Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20428000
CY2021Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1363000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
19065000
CY2020Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
13751000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1484000
CY2020Q4 nwbo Fair Value Of Embedded Conversion Option
FairValueOfEmbeddedConversionOption
2507000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
14774000
CY2021Q1 nwbo Debt Instrument Original Issue Discount Amount
DebtInstrumentOriginalIssueDiscountAmount
1000000
CY2021Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
4800000
CY2021Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
4500000
CY2021Q1 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
800000
CY2021Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
1700000
CY2020Q1 nwbo Capitalized Cost Amortization
CapitalizedCostAmortization
1400000
CY2021Q1 nwbo Capitalized Cost Amortization
CapitalizedCostAmortization
700000
CY2020Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
400000
CY2021Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
6700000
CY2021Q1 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
1900000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4123000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2626000
CY2020Q1 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
173000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
834605
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
640390
CY2020Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8468
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
834605
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
648858
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
700000
CY2021Q1 nwbo Stock Issued During Period Shares Warrant Exercises
StockIssuedDuringPeriodSharesWarrantExercises
2900000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5700000
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P20Y
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5100000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
331753
CY2020Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.28
CY2020 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y7M9D
CY2021Q1 nwbo Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
774
CY2021Q1 nwbo Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
2.00
CY2021Q1 nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
2688
CY2021Q1 nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
0.26
CY2021Q1 nwbo Number Of Warrants Warrants Cashless Exercise
NumberOfWarrantsWarrantsCashlessExercise
2552
CY2021Q1 nwbo Weighted Average Exercise Price Warrants Cashless Exercise
WeightedAverageExercisePriceWarrantsCashlessExercise
0.23
CY2021Q1 nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
885
CY2021Q1 nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
0.0337
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
326402
CY2021Q1 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.28
CY2021Q1 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y4M17D
CY2021Q1 nwbo Class Of Warrant Or Right Extended In Suspension
ClassOfWarrantOrRightExtendedInSuspension
256000000
CY2021Q1 nwbo Class Of Warrant Or Right Extended In Suspension
ClassOfWarrantOrRightExtendedInSuspension
262000000
CY2021Q1 nwbo Class Of Warrant Or Right Suspended
ClassOfWarrantOrRightSuspended
81000000
CY2021Q1 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2021Q1 nwbo Lessee Operating Additional Lease Term
LesseeOperatingAdditionalLeaseTerm
P3Y5M
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
255000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
244000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.120
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.120
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
611000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
978000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
987000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
893000
CY2021Q1 nwbo Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
9615000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13084000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7354000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5730000
CY2021Q1 nwbo Original Term Of Agreement
OriginalTermOfAgreement
P8M
CY2021Q1 nwbo Extended Term Of Agreement
ExtendedTermOfAgreement
P12M
CY2021Q2 nwbo Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
8700000
CY2021Q2 nwbo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1700000
CY2021Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
800000

Files In Submission

Name View Source Status
0001104659-21-068299-index-headers.html Edgar Link pending
0001104659-21-068299-index.html Edgar Link pending
0001104659-21-068299.txt Edgar Link pending
0001104659-21-068299-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nwbo-20210331.xsd Edgar Link pending
nwbo-20210331x10q.htm Edgar Link pending
nwbo-20210331x10q_htm.xml Edgar Link completed
nwbo-20210331xex31d1.htm Edgar Link pending
nwbo-20210331xex32d1.htm Edgar Link pending
nwbo-20210331_cal.xml Edgar Link unprocessable
nwbo-20210331_def.xml Edgar Link unprocessable
nwbo-20210331_lab.xml Edgar Link unprocessable
nwbo-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending